3 Global Penny Stocks With Market Caps Over US$80M To Watch

Global markets have shown resilience recently, with major U.S. stock indexes closing higher amid geopolitical developments and stable monetary policies. Amid these broader market movements, penny stocks continue to capture investor interest as they offer unique opportunities for growth. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still present significant value when supported by strong financials.

We're going to check out a few of the best picks from our screener tool.

Natural Food International Holding (SEHK:1837)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Natural Food International Holding Limited is an investment holding company that manufactures and sells natural health food products in China, with a market cap of HK$3.09 billion.

Operations: The company generates revenue of CN¥2.53 billion from the processing and selling of natural health products.

Market Cap: HK$3.09B

Natural Food International Holding has demonstrated strong financial performance, with earnings growth of 41.4% over the past year, surpassing both its five-year average and industry peers. The company maintains a stable financial position with more cash than debt and high-quality earnings. Its short-term assets significantly exceed liabilities, ensuring liquidity. Recent board changes include appointing Mr. Chou Hung Chi as an independent director, enhancing governance expertise. Despite a low return on equity at 15.7%, Natural Food trades below estimated fair value and declared a final dividend increase to HKD 0.069 per share for 2025, reflecting shareholder returns focus amidst stable volatility levels.

• Get an in-depth perspective on Natural Food International Holding's performance by reading our balance sheet health report here.
• Learn about Natural Food International Holding's future growth trajectory here.

Logory Logistics Technology (SEHK:2482)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Logory Logistics Technology Co., Ltd. offers road freight transportation services and solutions to various stakeholders in the logistics industry in China, with a market cap of HK$696.94 million.

Operations: The company's revenue of CN¥4.53 billion is generated from its digital freight businesses and related services.

Market Cap: HK$696.94M

Logory Logistics Technology faces challenges with negative earnings growth of 13.1% over the past year, contrasting its significant five-year average profit growth of 28.3%. Despite stable weekly volatility and a modest net profit margin increase to 1%, the company's debt-to-equity ratio has risen significantly from 19.1% to 46.7% over five years, indicating increased leverage risk. However, Logory's short-term assets (CN¥1.8 billion) exceed both its short-term and long-term liabilities, suggesting strong liquidity management. Recent board changes include appointing Mr. Liu Yunbo as an independent director, potentially strengthening governance amidst these financial dynamics.

• Click to explore a detailed breakdown of our findings in Logory Logistics Technology's financial health report.
• Review our historical performance report to gain insights into Logory Logistics Technology's track record.

Beijing Biostar Pharmaceuticals (SEHK:2563)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Beijing Biostar Pharmaceuticals Co., Ltd. is a synthetic biology-driven biopharmaceutical company focused on developing, manufacturing, and commercializing oncology products in China, with a market cap of HK$1.25 billion.

Operations: The company generates revenue of CN¥33.36 million from its research, development, manufacture, and sales of innovative drugs.

Market Cap: HK$1.25B

Beijing Biostar Pharmaceuticals, with a market cap of HK$1.25 billion, is navigating the complexities of the biotech sector with no debt burden and a stable cash runway exceeding one year. Despite reporting CN¥33.36 million in revenue, the company remains unprofitable but has managed to reduce losses by 3.8% annually over five years. Recent clinical trials for its oncology products have shown promising results, particularly in breast and ovarian cancer treatments, which could enhance future prospects. However, high share price volatility persists alongside significant governance changes following board member resignations and restructuring plans at its upcoming AGM.

• Unlock comprehensive insights into our analysis of Beijing Biostar Pharmaceuticals stock in this financial health report.
• Evaluate Beijing Biostar Pharmaceuticals' historical performance by accessing our past performance report.

Seize The Opportunity

• Embark on your investment journey to our 3,654 Global Penny Stocks selection here.
• Ready For A Different Approach? We've found 9 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com